DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis

Information source: Medical University of South Carolina
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis

Intervention: Alendronate (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Medical University of South Carolina

Official(s) and/or principal investigator(s):
Deborah A Bowlby, M.D., Principal Investigator, Affiliation: Medical University of South Carolina


OBJECTIVES: I. Determine the effects of alendronate sodium on skeletal remodeling and bone mineral density of the hip and spine in children with high-turnover idiopathic juvenile osteoporosis.

Clinical Details

Official title: A Non-Randomized, Open-Label, Prospective, Non-Controlled, 12-Month Clinical Trial to Determine the Effects of Alendronate 35 or 70 mg/Week Depending Upon Body Weight, in Children and Adolescent With IJO

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of Participants With Increased Bone Mineral Density

Secondary outcome: Participants (1) With Fractures Before and After Therapy,(2)Analysed for Average Changes From High to Near Normal Mineral Apposition Rate (MAR) After Therapy,(3)Analysed for Average Insignificant Changes in Biochemical Markers After Therapy.

Detailed description: PROTOCOL OUTLINE: Patients receive oral alendronate sodium weekly for 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.


Minimum age: 5 Years. Maximum age: 14 Years. Gender(s): Both.


Eligibility Criteria:

- 5-14 years of age

- Weight 20 kg or greater

- History of one or more atraumatic fracture

- Sexual development no greater than Tanner II

- Osteoporosis by DXA (Diagnosis of high-turnover osteoporosis with no underlying cause

(e. g., malignancy, hyperthyroidism, hyperparathyroidism, or vitamin D intoxication) Inclusion Criteria:

- Male and female children with a history of one or more atraumatic fractures, or

evidence of one or more compression fractures on radiographs of the spine (reduction of >20%).

- Bone mineral density by DXA at 2 standard deviations (SD) below normal mean for age

(Z-score at least 2 SD below normal mean at the lumbar spine or hip)

- Parental consent (and patient assent after age 12 years) to participate in the study.

- Sexual development at Tanner stage II or less (Prepubertal stage)

- Weight 20kg and more

Exclusion Criteria:

- History of severe gastritis or reflux

- Marked kyphoscoliosis or inability to sit or stand for at least 30 minutes.

- Abnormalities of the esophagus that delay emptying (e. g., strictures or achalasia)

- Hypersensitivity to bisphosphonates

- Uncorrected hypocalcemia

- History of gastric or duodenal ulcers

- Renal dysfunction as indicated by serum Creatinine greater than 1. 5 mg/dL

- Liver dysfunction as indicated by serum SGPT greater than 2 times upper limit of

normal for age or serum total bilirubin greater than 2. 0 mg/dL

- Diagnosis of osteogenesis imperfecta (including family history) or blue sclerae or


- Diagnosis of active rickets, osteomalacia, or bone alkaline phosphatase > 2 times

normal for age

- Severe gastritis or reflux

- Pregnancy

- Anorexia Nervosa

- Prior/Concurrent Therapy—

- Prior course of prednisone allowed

- No concurrent prednisone except inhaled steroids

- No concurrent high-dose glucocorticoids

- No concurrent salmon calcitonin

- No other concurrent bisphosphonates

- No concurrent long-term anti-seizure medication

Locations and Contacts

Medical University of South Carolina, Charleston, South Carolina 29425, United States
Additional Information

Starting date: September 2000
Last updated: October 21, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017